neoX Biotech

neoX Biotech is a Beijing-based biotech company founded in 2018 by co-founder and CEO Hang Chen, positioning itself as China's first company to focus on AI-driven biologic drug development . The company combines artificial intelligence, biophysics, and high-throughput experimentation to design drugs from first principles, with particular emphasis on large-molecule biologics and protein degraders (PROTAC) .

The company has raised substantial venture backing across multiple rounds. Its $30 million Series A in early 2021 was co-led by 5Y Capital and Sky9 Capital, with follow-on participation from BAI Capital, Vertex Ventures China, and existing backers Yuanjing Capital and Sequoia China . Less than six months later, it closed an A+ round of tens of millions of dollars led by Yuanbio Capital, bringing cumulative funding close to $100 million; 5Y Capital, Sequoia China, Sky9 Capital, and BAI Capital all reinvested . HongShan (formerly Sequoia China) also joined as an investor by 2023 . 5Y Capital in particular has backed neoX across all four of its funding rounds from inception through the A+ .

The company operates R&D centers in Beijing's Zhongguancun Life Science Park and Shanghai's Zhangjiang Hi-Tech Park, and has built partnerships with major pharmaceutical companies alongside its internal pipeline . In 2020, it received MIT Technology Review's "Best Innovation" award and won first prize in the HICOOL Global Entrepreneurship Competition .